Kathryn Balmanno
Overview
Explore the profile of Kathryn Balmanno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Balmanno K, Kidger A, Byrne D, Sale M, Nassman N, Eyers P, et al.
Biochem J
. 2023 Apr;
480(9):587-605.
PMID: 37018014
Innate or acquired resistance to small molecule BRAF or MEK1/2 inhibitors (BRAFi or MEKi) typically arises through mechanisms that sustain or reinstate ERK1/2 activation. This has led to the development...
2.
Sale M, Balmanno K, Cook S
Cancer Drug Resist
. 2022 May;
2(2):365-380.
PMID: 35582726
MEK1/2 inhibitors are clinically approved for the treatment of BRAF-mutant melanoma, where they are used in combination with BRAF inhibitors, and are undergoing evaluation in other malignancies. Acquired resistance to...
3.
Prescott J, Balmanno K, Mitchell J, Okkenhaug H, Cook S
Biochem J
. 2022 Jan;
479(3):305-325.
PMID: 35029639
Inhibitor of kappa B (IκB) kinase β (IKKβ) has long been viewed as the dominant IKK in the canonical nuclear factor-κB (NF-κB) signalling pathway, with IKKα being more important in...
4.
Kidger A, Munck J, Saini H, Balmanno K, Minihane E, Courtin A, et al.
Mol Cancer Ther
. 2019 Nov;
19(2):525-539.
PMID: 31748345
The RAS-regulated RAF-MEK1/2-ERK1/2 signaling pathway is frequently deregulated in cancer due to activating mutations of growth factor receptors, RAS or BRAF. Both RAF and MEK1/2 inhibitors are clinically approved and...
5.
Odle R, Walker S, Oxley D, Kidger A, Balmanno K, Gilley R, et al.
Mol Cell
. 2019 Nov;
77(2):228-240.e7.
PMID: 31733992
Since nuclear envelope breakdown occurs during mitosis in metazoan cells, it has been proposed that macroautophagy must be inhibited to maintain genome integrity. However, repression of macroautophagy during mitosis remains...
6.
Sale M, Balmanno K, Saxena J, Ozono E, Wojdyla K, McIntyre R, et al.
Nat Commun
. 2019 May;
10(1):2030.
PMID: 31048689
Acquired resistance to MEK1/2 inhibitors (MEKi) arises through amplification of BRAF or KRAS to reinstate ERK1/2 signalling. Here we show that BRAF amplification and MEKi resistance are reversible following drug...
7.
Hey F, Andreadi C, Noble C, Patel B, Jin H, Kamata T, et al.
Heliyon
. 2019 Jan;
4(12):e01065.
PMID: 30603699
BRAF is a cytoplasmic protein kinase, which activates the MEK-ERK signalling pathway. Deregulation of the pathway is associated with the presence of mutations in human cancer, the most common being...
8.
Darling N, Balmanno K, Cook S
PLoS One
. 2017 Sep;
12(9):e0184907.
PMID: 28931068
Disruption of protein folding in the endoplasmic reticulum (ER) causes ER stress. Activation of the unfolded protein response (UPR) acts to restore protein homeostasis or, if ER stress is severe...
9.
Galloway A, Saveliev A, Lukasiak S, Hodson D, Bolland D, Balmanno K, et al.
Science
. 2016 Apr;
352(6284):453-9.
PMID: 27102483
Progression through the stages of lymphocyte development requires coordination of the cell cycle. Such coordination ensures genomic integrity while cells somatically rearrange their antigen receptor genes [in a process called...
10.
Ashford A, Dunkley T, Cockerill M, Rowlinson R, Baak L, Gallo R, et al.
Cell Mol Life Sci
. 2015 Sep;
73(4):883-900.
PMID: 26346493
The dual-specificity tyrosine-phosphorylation-regulated kinase, DYRK1B, is expressed de novo during myogenesis, amplified or mutated in certain cancers and mutated in familial cases of metabolic syndrome. DYRK1B is activated by cis...